Lenovo unveils an AI-powered 3D avatar to support dementia care

Chinese-American multinational technology company, Lenovo, in collaboration with UK-based community interest company (CIC), Innovations in Dementia, has launched Alzheimer’s Intelligence, an innovative proof-of-concept project featuring a photorealistic 3D avatar designed to assist individuals diagnosed with dementia and Alzheimer’s. The AI-based […]

IHH Healthcare completes US$890 mn takeover of Island Hospital

IHH Healthcare, a leading integrated healthcare provider, has finalised its acquisition of Island Hospital, a 600-bed facility in Penang, Malaysia, for approximately MYR3.9 billion (US$890 million). This strategic move expands IHH’s footprint in Malaysia to 18 hospitals, strengthening its presence, […]

Calamities may dampen NR supply – ANRPC report

Philippine researchers have developed a smart polymer with promising biomedical applications. Their study, published on August 10, 2024, highlights the polymer’s adaptability to environmental changes. This team focused on “stimuli-responsive” polymers, which react to changes in temperature or pH, with […]

Study cracks new insights into ovarian cancer’s immune evasion

Researchers at Weill Cornell Medicine have identified a novel mechanism by which ovarian tumors hinder the immune system’s T cells, blocking their energy supply and limiting their effectiveness against cancer. This discovery, published in Nature, highlights a potential new immunotherapy […]

Cancer Biologists Uncover a New Mechanism for an Old Chemo Drug

MIT cancer researchers have discovered surprising mechanism for the long-used chemotherapy drug 5-fluorouracil (5-FU), indicating a potential shift in cancer treatment protocols. Previously believed to work primarily by damaging DNA, this research demonstrates that 5-FU effectively kills colon and gastrointestinal […]

Takeda funds drug research

May 4, 2012

JAPAN – Takeda Pharmaceutical Co. Ltd has joined the Structural Genomics Consortium(SGC) to fund collective drug research aimed at bringing new, more effective medicines to market faster.

The SGC is a not-for-profit organization based at the Universities of Toronto, Canada, and Oxford, England. It supports the discovery of new medicines by more than 200 scientists from academia and industry who make all early-stage research openly available with no patents or restrictions.

Takeda’s contribution raises the total from US$13 million to US$50 million in support of the SGC by six of the world’s leading pharmaceutical companies. Takeda will also participate on the SGC Scientific Committee and its Board of Directors.

“As a global leader in research, Takeda is dedicated to helping change the way drug discovery is conducted,” said Paul Chapman, General Manager, Pharmaceutical Research Division, Takeda.

“We are very excited about the opportunity to become a part of the SGC, and firmly believe that important new medicines will be discovered in industry and vital scientific knowledge will be gained in academia through this open innovation.”